Access Biotechnology is an investment arm of Access Industries that focuses on private and public biopharma companies.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs. The company is based in New York.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2019 | Disc Medicine | Series A | 50M |
9/2022 | Nimbus Therapeutics | Venture Round | 0 |
7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
7/2022 | Areteia Therapeutics | Series A | 0 |
9/2021 | Disc Medicine | Post-IPO Equity | 0 |
9/2021 | Disc Medicine | Series B | 90M |
2/2023 | Hemab | Series B | 0 |
8/2022 | Disc Medicine | Post-IPO Equity | 0 |
2/2021 | Day One Biopharmaceuticals | Series B | 130M |
4/2020 | Pandion Therapeutics | Series B | 80M |
12/2021 | Curie Therapeutics | Series A | 75M |
6/2023 | Upstream Bio | Series B | 0 |
3/2021 | DTx Pharma | Series B | 100M |
7/2020 | Verona Pharma | Private Placement | 200M |
11/2021 | Recludix Pharma | Series A | 60M |
9/2022 | ACELYRIN | Series C | 0 |
6/2022 | Upstream Bio | Series A | 200M |
5/2021 | Eliem Therapeutics | Series B | 0 |
3/2021 | Eliem Therapeutics | Series A | 80M |
11/2021 | Matchpoint Therapeutics | Seed | 30M |
2/2023 | Hemab | Series B | 0 |
9/2022 | ACELYRIN | Series C | 0 |
9/2022 | Nimbus Therapeutics | Venture Round | 0 |
8/2022 | Disc Medicine | Post-IPO Equity | 0 |
7/2022 | Areteia Therapeutics | Series A | 0 |
6/2022 | Upstream Bio | Series A | 0 |
12/2021 | Curie Therapeutics | Series A | 0 |
11/2021 | Recludix Pharma | Series A | 0 |
11/2021 | Matchpoint Therapeutics | Seed Round | 0 |
9/2021 | Disc Medicine | Post-IPO Equity | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|